Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

56 Biosimilars In Late-Stage Development Line Up To Challenge Top Biologic Drugs

Executive Summary

Many key biologic drugs, including adalimumab, bevacizumab, rituximab and trastuzumab, are facing biosimilar competition from products that have been either filed or recently approved in Europe, and 56 biosimilars are now at a late stage of clinical development, according to Per Troein of QuintilesIMS.

You may also be interested in...



2017 – Scrip Readers’ Pharma Year In Review

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

2017 – Scrip Readers’ Pharma Year In Review

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

Rerouting Drug Supplies ‘A Priority’ After Brexit Transition Ends

Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel